AstraZeneca has been developing cancer medicines for more than 40 years. Many of these have increased survival rates for patients in the UK and around the world. Even as R&D continues to push boundaries in how we understand and fight cancer, there is still more to do.
We are at the heart of oncology R&D in the UK and are committed to advancing the science of oncology to deliver life-changing medicines. Our ambition is to eliminate cancer as a cause of death through scientific discovery and collaborations and ensure that these reach people in most need.
Faslodex (fulvestrant) is indicated for the treatment of oestrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy, or with disease relapse on or after adjuvant antioestrogen therapy, or disease progression on antioestrogen therapy.
Iressa (gefitinib) is indicated as monotherapy for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of EGFR-TK.
Lynparza▼ (olaparib) is a first‐in‐class PARP inhibitor (PARPi) that allows women with BRCA mutated (BRCAm) platinum‐sensitive relapsed ovarian cancer to extend progression‐free survival (PFS).
TAGRISSO▼ (osimertinib) is indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small-cell lung cancer (NSCLC).
Zoladex® (goserelin) is a Luteinising Hormone-Releasing Hormone analogue (LHRHa). Zoladex® is available as a 3.6 mg implant and a 10.8 mg implant in a pre-filled syringe.
GB-9390 - October 2017